HAL-RAR Technique for Treating Hemorrhoids
Launched by AMALIA FLEMING GENERAL HOSPITAL · Feb 26, 2021
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
This is a retrospective, single-institution, study conducted from January 2010 to November 2019. Grade of hemorrhoidal disease was assessed according to Goligher's classification. Patients with grade II, resistant to conservative treatment, grade III and IV hemorrhoidal disease that underwent the HAL-RAR technique, were included in the study. Patients with grade II disease presented a small degree of prolapse. Non-surgical techniques, such as rubber-band ligation or injection of sclerosing agents, were not performed prior to the HAL-RAR operation since this is not a common practice in our i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with
- • grade II hemorrhoidal disease, resistant to conservative treatment
- • grade III hemorrhoidal disease,
- • grade IV hemorhoidal disease,
- • that underwent the HAL-RAR technique.
- Exclusion Criteria:
- • pregnancy
- • coagulation disorders
- • patients with major comorbidities (American Society of Anesthesiologists \[ASA\] ≥3),
- • psychiatric conditions preventing collaboration and follow-up
- • other concomitant anorectal disease (rectal prolapse, anal fissure, anal stenosis, perianal fistula or abscess, fecal incontinence)
- • previous pelvic radiotherapy
- • declined consent
About Amalia Fleming General Hospital
Amalia Fleming General Hospital is a prominent healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence, the hospital integrates a multidisciplinary approach, harnessing the expertise of leading medical professionals and researchers. The facility is equipped with state-of-the-art technology, ensuring the highest standards of safety and efficacy in clinical research. Amalia Fleming General Hospital aims to contribute to the development of new therapies and treatments, enhancing health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Georgia Dedemadi, MD, PhD
Principal Investigator
Amalia Fleming Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials